Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia.

MLA

Polak, Roel, et al. “Autophagy Inhibition as a Potential Future Targeted Therapy for ETV6-RUNX1-Driven B-Cell Precursor Acute Lymphoblastic Leukemia.” Haematologica, vol. 104, no. 4, Apr. 2019, pp. 738–48. EBSCOhost, https://doi.org/10.3324/haematol.2018.193631.

APA

Polak, R., Bierings, M. B., van der Leije, C. S., Sanders, M. A., Roovers, O., Marchante, J. R. M., Boer, J. M., Cornelissen, J. J., Pieters, R., den Boer, M. L., & Buitenhuis, M. (2019). Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Haematologica, 104(4), 738–748. https://doi.org/10.3324/haematol.2018.193631

Chicago

Polak, Roel, Marc B Bierings, Cindy S van der Leije, Mathijs A Sanders, Onno Roovers, João R M Marchante, Judith M Boer, et al. 2019. “Autophagy Inhibition as a Potential Future Targeted Therapy for ETV6-RUNX1-Driven B-Cell Precursor Acute Lymphoblastic Leukemia.” Haematologica 104 (4): 738–48. doi:10.3324/haematol.2018.193631.